{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:13:42Z","timestamp":1776316422405,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"USM Research University Grant","award":["1001\/PPSP\/812137"],"award-info":[{"award-number":["1001\/PPSP\/812137"]}]},{"name":"USM Neuroscience Excellence Grant","award":["304.PPSP.652205.K134"],"award-info":[{"award-number":["304.PPSP.652205.K134"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0317-7","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T23:45:58Z","timestamp":1439250358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis"],"prefix":"10.1186","volume":"10","author":[{"given":"Teguh Haryo","family":"Sasongko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Farrah Dila","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nik Mohamad Ariff","family":"Nik Abdul Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z. A. M. H.","family":"Zabidi-Hussin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"issue":"4","key":"317_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354. doi: 10.1016\/j.pediatrneurol.2013.08.001 .","journal-title":"Pediatr Neurol"},{"issue":"13","key":"317_CR2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356. doi: 10.1056\/NEJMra055323 .","journal-title":"N Engl J Med"},{"issue":"9","key":"317_CR3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00247-008-0832-y","volume":"38","author":"HJ Baskin Jr","year":"2008","unstructured":"Baskin Jr HJ. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol. 2008;38(9):936\u201352. doi: 10.1007\/s00247-008-0832-y .","journal-title":"Pediatr Radiol"},{"issue":"3","key":"317_CR4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.yebeh.2008.05.010","volume":"13","author":"CM Kopp","year":"2008","unstructured":"Kopp CM, Muzykewicz DA, Staley BA, Thiele EA, Pulsifer MB. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav. 2008;13(3):505\u201310. doi: 10.1016\/j.yebeh.2008.05.010 .","journal-title":"Epilepsy Behav"},{"key":"317_CR5","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","volume":"14 Spec No. 2","author":"DJ Kwiatkowski","year":"2005","unstructured":"Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005;14 Spec No. 2:R251\u20138. doi: 10.1093\/hmg\/ddi260 .","journal-title":"Hum Mol Genet"},{"issue":"1","key":"317_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1528-1167.2007.01270.x","volume":"49","author":"M Wong","year":"2008","unstructured":"Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia. 2008;49(1):8\u201321. doi: 10.1111\/j.1528-1167.2007.01270.x .","journal-title":"Epilepsia"},{"issue":"1","key":"317_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1528-1167.2008.01814.x","volume":"50","author":"P Major","year":"2009","unstructured":"Major P, Rakowski S, Simon MV, Cheng ML, Eskandar E, Baron J, et al. Are cortical tubers epileptogenic? Evidence from electrocorticography. Epilepsia. 2009;50(1):147\u201354. doi: 10.1111\/j.1528-1167.2008.01814.x .","journal-title":"Epilepsia"},{"issue":"8","key":"317_CR8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000142039.14522.1A","volume":"63","author":"S Goh","year":"2004","unstructured":"Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology. 2004;63(8):1457\u201361.","journal-title":"Neurology"},{"issue":"9","key":"317_CR9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/08830738040190091001","volume":"19","author":"DN Franz","year":"2004","unstructured":"Franz DN. Non-neurologic manifestations of tuberous sclerosis complex. J Child Neurol. 2004;19(9):690\u20138.","journal-title":"J Child Neurol"},{"issue":"5","key":"317_CR10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1183\/09031936.06.00113303","volume":"27","author":"SR Johnson","year":"2006","unstructured":"Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056\u201365. doi: 10.1183\/09031936.06.00113303 .","journal-title":"Eur Respir J"},{"issue":"10","key":"317_CR11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","volume":"14","author":"JR Yates","year":"2006","unstructured":"Yates JR. Tuberous sclerosis. Eur J Hum Genet. 2006;14(10):1065\u201373. doi: 10.1038\/sj.ejhg.5201625 .","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"317_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","volume":"12","author":"PT Bhaskar","year":"2007","unstructured":"Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007;12(4):487\u2013502. doi: 10.1016\/j.devcel.2007.03.020 .","journal-title":"Dev Cell"},{"issue":"3","key":"317_CR13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11910-012-0269-4","volume":"12","author":"DN Franz","year":"2012","unstructured":"Franz DN, Weiss BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 2012;12(3):294\u2013301. doi: 10.1007\/s11910-012-0269-4 .","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"317_CR14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1101\/gad.901101","volume":"15","author":"X Gao","year":"2001","unstructured":"Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001;15(11):1383\u201392. doi: 10.1101\/gad.901101 .","journal-title":"Genes Dev"},{"issue":"34","key":"317_CR15","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","volume":"277","author":"EA Goncharova","year":"2002","unstructured":"Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277(34):30958\u201367. doi: 10.1074\/jbc.M202678200 .","journal-title":"J Biol Chem"},{"issue":"9","key":"317_CR16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648\u201357. doi: 10.1038\/ncb839 .","journal-title":"Nat Cell Biol"},{"issue":"5","key":"317_CR17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","volume":"11","author":"DJ Kwiatkowski","year":"2002","unstructured":"Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002;11(5):525\u201334.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"317_CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell. 2002;10(1):151\u201362.","journal-title":"Mol Cell"},{"issue":"9","key":"317_CR19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncb840","volume":"4","author":"CJ Potter","year":"2002","unstructured":"Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4(9):658\u201365. doi: 10.1038\/ncb840 .","journal-title":"Nat Cell Biol"},{"issue":"1\u20134","key":"317_CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","volume":"1","author":"LM Ballou","year":"2008","unstructured":"Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1\u20134):27\u201336. doi: 10.1007\/s12154-008-0003-5 .","journal-title":"J Chem Biol"},{"key":"317_CR21","volume-title":"RxList: The internet drug index","author":"Rapamune","year":"2013","unstructured":"Rapamune. RxList: The internet drug index. 2013."},{"issue":"2","key":"317_CR22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molmed.2010.10.002","volume":"17","author":"D Ehninger","year":"2011","unstructured":"Ehninger D, Silva AJ. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med. 2011;17(2):78\u201387. doi: 10.1016\/j.molmed.2010.10.002 .","journal-title":"Trends Mol Med"},{"issue":"3","key":"317_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Gene Chromosome Cancer. 2005;42(3):213\u201327. doi: 10.1002\/gcc.20118 .","journal-title":"Gene Chromosome Cancer"},{"issue":"7","key":"317_CR24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","volume":"99","author":"L Fischer","year":"2015","unstructured":"Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation. 2015;99(7):1455\u201362. doi: 10.1097\/TP.0000000000000555 .","journal-title":"Transplantation"},{"issue":"10","key":"317_CR25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jcin.2013.05.016","volume":"6","author":"F Ribichini","year":"2013","unstructured":"Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, et al. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). JACC Cardiovasc Interv. 2013;6(10):1012\u201322. doi: 10.1016\/j.jcin.2013.05.016 .","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"317_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2015.04.063","volume":"66","author":"F Alfonso","year":"2015","unstructured":"Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. A prospective randomized trial of drug-eluting balloons versus Everolimus-Eluting stents in patients with in-stent restenosis of drug-eluting stents: the ribs IV randomized clinical trial. J Am Coll Cardiol. 2015;66(1):23\u201333. doi: 10.1016\/j.jacc.2015.04.063 .","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"317_CR27","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256\u201365. doi: 10.1002\/cncr.25219 .","journal-title":"Cancer"},{"issue":"7","key":"317_CR28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","volume":"26","author":"A Ravaud","year":"2015","unstructured":"Ravaud A, Barrios CH, Alekseev B, Tay MH, Agarwala SS, Yalcin S, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1378\u201384. doi: 10.1093\/annonc\/mdv170 .","journal-title":"Ann Oncol"},{"issue":"1","key":"317_CR29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2012-0263","volume":"18","author":"D Castellano","year":"2013","unstructured":"Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O\u2019Dorisio T, et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46\u201353. doi: 10.1634\/theoncologist.2012-0263 .","journal-title":"Oncologist"},{"issue":"9808","key":"317_CR30","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005\u201312. doi: 10.1016\/S0140-6736(11)61742-X .","journal-title":"Lancet"},{"issue":"10","key":"317_CR31","first-page":"3333","volume":"7","author":"L Qiao","year":"2014","unstructured":"Qiao L, Liang Y, Mira RR, Lu Y, Gu J, Zheng Q. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2014;7(10):3333\u201343.","journal-title":"Int J Clin Exp Med"},{"key":"317_CR32","doi-asserted-by":"crossref","unstructured":"Sasongko TH IN, Nik Abdul Malik NMA, Zabidi-Hussin ZAMH. Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex (Protocol). Cochrane Database Syst Rev 2014 (9). doi: 10.1002\/14651858.CD011272.pub2 .","DOI":"10.1002\/14651858.CD011272.pub2"},{"issue":"7","key":"317_CR33","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371\/journal.pmed.1000097 .","journal-title":"PLoS Med"},{"key":"317_CR34","unstructured":"Higgins JPT GSe. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011."},{"key":"317_CR35","unstructured":"Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"317_CR36","unstructured":"Wells GA Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp . Accessed 1 May 2015"},{"issue":"7414","key":"317_CR37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. doi: 10.1136\/bmj.327.7414.557 .","journal-title":"BMJ"},{"issue":"1","key":"317_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2006.07.017","volume":"18","author":"I Herry","year":"2007","unstructured":"Herry I, Neukirch C, Debray MP, Mignon F, Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med. 2007;18(1):76\u20137. doi: 10.1016\/j.ejim.2006.07.017 .","journal-title":"Eur J Intern Med"},{"issue":"11","key":"317_CR39","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/ndt\/gfq456","volume":"25","author":"R Peces","year":"2010","unstructured":"Peces R, Peces C, Cuesta-Lopez E, Perez-Duenas V, Vega-Cabrera C, Azorin S, et al. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant. 2010;25(11):3787\u201391. doi: 10.1093\/ndt\/gfq456 .","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"317_CR40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351. doi: 10.1056\/NEJMoa063564 .","journal-title":"N Engl J Med"},{"issue":"10","key":"317_CR41","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0883073808321764","volume":"23","author":"MK Koenig","year":"2008","unstructured":"Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23(10):1238\u20139. doi: 10.1177\/0883073808321764 .","journal-title":"J Child Neurol"},{"issue":"6","key":"317_CR42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pediatrneurol.2010.01.016","volume":"42","author":"SP Sparagana","year":"2010","unstructured":"Sparagana SP, Wilkes DC, Thompson CE, Bowers DC. Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus. Pediatr Neurol. 2010;42(6):443\u20136. doi: 10.1016\/j.pediatrneurol.2010.01.016 .","journal-title":"Pediatr Neurol"},{"issue":"1","key":"317_CR43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00381-010-1222-y","volume":"27","author":"M Yalon","year":"2011","unstructured":"Yalon M, Ben-Sira L, Constantini S, Toren A. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst. 2011;27(1):179\u201381. doi: 10.1007\/s00381-010-1222-y .","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"317_CR44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490\u20138. doi: 10.1002\/ana.20784 .","journal-title":"Ann Neurol"},{"issue":"4","key":"317_CR45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3171\/2010.7.PEDS10221","volume":"6","author":"A Birca","year":"2010","unstructured":"Birca A, Mercier C, Major P. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr. 2010;6(4):381\u20134. doi: 10.3171\/2010.7.PEDS10221 .","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"317_CR46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/pbc.22298","volume":"54","author":"C Lam","year":"2010","unstructured":"Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 2010;54(3):476\u20139. doi: 10.1002\/pbc.22298 .","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"317_CR47","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2006.05.018","volume":"48","author":"R Wienecke","year":"2006","unstructured":"Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis. 2006;48(3):e27\u20139. doi: 10.1053\/j.ajkd.2006.05.018 .","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"317_CR48","first-page":"292","volume":"31","author":"C Cabrera Lopez","year":"2011","unstructured":"Cabrera Lopez C, Marti T, Catala V, Torres F, Mateu S, Ballarin Castan J, et al. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. Nefrologia. 2011;31(3):292\u20138. doi: 10.3265\/Nefrologia.pre2011.Apr.10812 .","journal-title":"Nefrologia"},{"issue":"9","key":"317_CR49","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario Jr FJ, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011;6(9):e23379. doi: 10.1371\/journal.pone.0023379 .","journal-title":"PLoS One"},{"issue":"12","key":"317_CR50","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071\u201381. doi: 10.1158\/1078-0432.CCR-11-0445 .","journal-title":"Clin Cancer Res"},{"issue":"19","key":"317_CR51","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311. doi: 10.1056\/NEJMoa1001671 .","journal-title":"N Engl J Med"},{"issue":"1","key":"317_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"1","key":"317_CR53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D36TB7N61M","volume":"18","author":"T Truchuelo","year":"2012","unstructured":"Truchuelo T, Diaz-Ley B, Rios L, Alcantara J, Jaen P. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J. 2012;18(1):15.","journal-title":"Dermatol Online J"},{"issue":"1","key":"317_CR54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","volume":"148","author":"M Wataya-Kaneda","year":"2012","unstructured":"Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol. 2012;148(1):138\u20139. doi: 10.1001\/archderm.148.1.138 .","journal-title":"Arch Dermatol"},{"issue":"7","key":"317_CR55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0883073813488664","volume":"28","author":"JW Wheless","year":"2013","unstructured":"Wheless JW, Almoazen H. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J Child Neurol. 2013;28(7):933\u20136. doi: 10.1177\/0883073813488664 .","journal-title":"J Child Neurol"},{"issue":"1","key":"317_CR56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","volume":"53","author":"RS Foster","year":"2012","unstructured":"Foster RS, Bint LJ, Halbert AR. Topical 0.1\u00a0% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53(1):52\u20136. doi: 10.1111\/j.1440-0960.2011.00837.x .","journal-title":"Australas J Dermatol"},{"key":"317_CR57","doi-asserted-by":"crossref","unstructured":"Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013. doi: 10.1002\/ana.23960 .","DOI":"10.1002\/ana.23960"},{"key":"317_CR58","doi-asserted-by":"crossref","unstructured":"Canpolat M, Per H, Gumus H, Yikilmaz A, Unal E, Patiroglu T et al. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86. Childs Nerv Syst 2013. doi: 10.1007\/s00381-013-2185-6 .","DOI":"10.1007\/s00381-013-2185-6"},{"issue":"5","key":"317_CR59","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1542\/peds.2010-2910","volume":"127","author":"D Tiberio","year":"2011","unstructured":"Tiberio D, Franz DN, Phillips JR. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics. 2011;127(5):e1335\u20137. doi: 10.1542\/peds.2010-2910 .","journal-title":"Pediatrics"},{"issue":"7","key":"317_CR60","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/pbc.22401","volume":"54","author":"JG Pressey","year":"2010","unstructured":"Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010;54(7):1035\u20137. doi: 10.1002\/pbc.22401 .","journal-title":"Pediatr Blood Cancer"},{"issue":"9861","key":"317_CR61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332. doi: 10.1016\/S0140-6736(12)61134-9 .","journal-title":"Lancet"},{"issue":"9869","key":"317_CR62","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324. doi: 10.1016\/S0140-6736(12)61767-X .","journal-title":"Lancet"},{"issue":"3","key":"317_CR63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12(3):121\u20136. doi: 10.2165\/11634580-000000000-00000 .","journal-title":"Drugs R D"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0317-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T13:15:22Z","timestamp":1718025322000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/10\/1\/95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,12]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0317-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,12]]},"article-number":"95"}}